

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/599,982
Filing Date	October 16, 2006
First Named Inventor	Wade S. Blair
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC32600A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US 5,422,358	06-06-1995	Cross P., et al	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AB	WO 03/035076	05/01/2003	Instituto di Ricerche di Biologia Molecolare P. Angeletti Spa		
	AC	WO 90/05133	05/17/1990	Pfizer Limited – GB Pfizer Inc. - US		
	AD	WO 03/049690	06/19/2003	Bristol-Myers		
	AE	EP 0376358 A1	07/04/1990	Pfizer Inc.		
	AF	WO 03/062238	07/31/2003	Bristol-Myers Squibb Company		
	AG	WO 03/062204	07/31/2003	Merck & Co., Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AH	ANGLIKER, H., "Synthesis Of Tight Binding Inhibitors And Their Action On The Proprotein- Processing Enzyme Furin," <i>J. Med. Chem.</i> , 1995, 4014-4018, vol. 38.	
	AI	BAHBOUHI, B., et al., "Replication Of HIV-1 Viruses In The Presence Of The Portland $\alpha$ 1- Antitrypsin Variant ( $\alpha$ 1-PDX) Inhibitor," <i>Biochem. J.</i> , 2001, 127-134, vol. 360.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/599,982
Filing Date	October 16, 2006
First Named Inventor	Wade S. Blair
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC32600A

AJ	BLAIR, W., et al., "A Novel HIV-1 Antiviral High Throughput Screening Approach For The Discovery Of HIV-1 Inhibitors," <i>Antiviral Research</i> , 2005, 107-116, vol. 65.
AK	CAO, J., et al., "High-Throughput Human Immunodeficiency Virus Type 1 (HIV-1) Full Replication Assay That Includes HIV-1 Vif As An Antiviral Target," <i>Antimicrobial Agents And Chemotherapy</i> , 2005, 3833-3841, vol. 49, no. 9.
AL	DEJESUS, E., et al., "The HIV Integrase Inhibitor GS-9137 (JTK-303) Exhibits Potent Antiviral Activity In Treatment-Naïve And Experienced Patients," <i>Thirteenth Conference Retroviruses and Opportunistic Infections</i> , 2006, Abstract. <u>HIV Drug Resistance: Mechanisms and Impact on Response to New Agents</u> , AN: 160LB.
AM	DUBAY, J., et al., "Analysis Of The Cleavage Site Of The Human Immunodeficiency Virus Type 1 Glycoprotein: Requirement Of Precursor Cleavage For Glycoprotein Incorporation," <i>J. Virol.</i> , 1995, 4675-4682, vol. 69, no. 8.
AN	DUNN, J., et al., "Analgetic And Antiinflammatory 7-Aroylbenzofuran-5-Ylactic Acids And 7-Aroylbenzothiophene-5-Ylactic Acids," <i>J. Med. Chem.</i> , 1986, 2326-2329, vol. 29.
AO	FÄTKENHEUER, G., et al., "Evaluation Of Dosing Frequency And Food Effect On Viral Load Reduction During Short-Term Monotherapy With UK-427,857 A Novel CCR5 Antagonist," Abstract. <i>Fifteenth International AIDS Conference</i> , 2004 AN: TuPeB4489.
AP	GARTEN, W., et al., "Processing Of Viral Glycoproteins By The Subtilisin-Like Endoprotease Furin And Its Inhibition By Specific Peptidylchloroalkylketones," <i>Biochimie</i> , 1994, 217-225, vol. 76.
AQ	HALLENBERGER, S., et al., "Inhibition Of Furin-Mediated Cleavage Activation Of HIV-1 Glycoprotein gp160", <i>Nature</i> , 1992, 358-361, vol. 360.
AR	HANNA, G., et al., "Antiviral Activity, Safety, And Tolerability Of A Novel, Oral Small-Molecule HIV-1 Attachment Inhibitor, BMS-488043, In HIV-1-Infected Subjects A Novel, Oral Small-Molecule HIV-1 Attachment Inhibitor, BMS-488043, in HIV-1-Infected Subjects", Abstract. <i>Eleventh Conference Retroviruses and Opportunistic Infections</i> , 2004, <u>Pharmacology and New Antiretroviral Agents</u> , AN: 141.
AS	JOSE, E.S., et al., "Megalomycin Inhibits HIV-1 Replication And Interferes With gp160 Processing," <i>Virology</i> , 1997, 303-314, vol. 239.
AT	KOWALSKI, M., et al., "Functional Regions Of The Envelope Glycoprotein Of Human Immunodeficiency Virus Type 1," <i>Science</i> , 1987, 1351-1355, vol. 237.
AU	KWONG, P., et al., "Structure Of An HIV gp120 Envelope Glycoprotein In Complex With The CD4 Receptor And A Neutralizing Human Antibody," <i>Nature</i> , 1998, 648-659, vol. 393.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/599,982
Filing Date	October 16, 2006
First Named Inventor	Wade S. Blair
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC32600A

AV	LEONARD, C., et al., "Assignment Of Intrachain Disulfide Bonds And Characterization Of Potential Glycosylation Sites Of The Type 1 Recombinant Human Immunodeficiency Virus Envelope Glycoprotein (gp120) Expressed In Chinese Hamster Ovary Cells," <i>J. Biol. Chem.</i> , 1990, 10373-10382, vol. 265, no. 18.
AW	LITTLE, S., et al., Antiretroviral Effect Of L-000870810, A Novel HIV-1 Integrase Inhibitor, In HIV-1-Infected Patients, Abstract. <i>Twelfth Conference Retroviruses and Opportunistic Infections</i> , 2005, <u>Antiretroviral Therapy: New Agents, New Combinations, and Virologic Responses</u> , AN: 161.
AX	MARTIN, D., et al., "PA-457, The First-In-Class Maturation Inhibitor, Exhibits Antiviral Activity Following A Single Oral Dose In HIV-1-Infected Patients," Abstract. <i>Twelfth Conference Retroviruses and Opportunistic Infections</i> , 2005, <u>Antiretroviral Therapy: New Agents, New Combinations, and Virologic Responses</u> , AN: 159.
AY	MCCUNE, J., et al., "Endoproteolytic Cleavage Of gp160 Is Required For The Activation Of Human Immunodeficiency Virus," <i>Cell</i> , 1988, 55-67, vol. 53.
AZ	MORALES-RAMIREZ, J., et al., Antiretroviral Effect Of MK-0518, A Novel HIV-1 Integrase Inhibitor, In ART-Naïve HIV-Infected Patients", Abstract. <i>Tenth European Aids Conference</i> , 2005, <u>Initiation of Antiretroviral Therapy</u> , AN: LBPS1/6.
BA	MOULARD, M., et al., "Maturation Of HIV Envelope Glycoprotein Precursors By Cellular Endoproteases," <i>Biochimica Et Biophysica Acta</i> , 2000, 121-132, vol. 1469.
BB	PAL, R., et al., "Processing Of The Structural Proteins Of Human Immunodeficiency Virus Type 1 In The Presence Of Monensin And Cerulenin," <i>Proc. Natl. Acad. Sci.</i> , 1988, 9283-9286, vol. 85.
BC	PAL, R., et al., "Role Of Oligosaccharides In The Processing And Maturation Of Envelope Glycoproteins Of Human Immunodeficiency Virus Type 1," <i>Proc. Natl. Acad. Sci.</i> , 1989, 3384-3388, vol. 86.
BD	WALKER, B., et al., "Inhibition Of Human Immunodeficiency Virus Syncytium Formation And Virus Replication By Castanospermine," <i>Proc. Natl. Acad. Sci.</i> , 1987, 8120-8124, vol. 84.
BE	WANG, T., et al., "Discovery Of 4-Benzoyl-1-[(4-Methoxy-1H-Pyrrolo[2,3-b]Pyridin-3-yl)Oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes With CD4-gp120 Interactions," <i>J. Med. Chem.</i> , 2003, 4236-4239, vol. 46.
BF	WEISLOW, O., et al., "New Soluble-Formazan Assay For HIV-1 Cytopathic Effects: Application To High-Flux Screening Of Synthetic And Natural Products For AIDS-Antiviral Activity," <i>J. Natl. Cancer Inst.</i> , 1989, 577-586, vol. 81, no. 8.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/599,982
Filing Date	October 16, 2006
First Named Inventor	Wade S. Blair
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	PC32600A

BG	WILD, C., et al., "PA-457 Is A Small Molecule Inhibitor Of HIV-1 Budding/Maturation That Potently Inhibits Replication Of Virus Isolates Resistant To All Classes Of Approved Drugs," Abstract. <i>Tenth European Aids Conference</i> , 2003, AN: 14.
BH	YENI, P., et al, "Treatment For Adult HIV Infection: 2004 Recommendations Of The International AIDS Society-USA Panel," <i>JAMA</i> , 2004, 251-265, vol. 292, no. 2.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.